Health Canada Approves XEOMIN (IncobotulinumtoxinA) for Treatment of Post-Stroke Lower Limb Spasticity

 This is the whole problem with spasticity; TREATING, NOT CURING! Don't we have anyone in stroke smart enough to cure spasticity?  Instead we get the infuriating opinion of Dr. William M. Landau that seems to have short-circuited spasticity research. Schadenfreude can't come soon enough for him.

Spasticity After Stroke: Why Bother? Aug. 2004)

The latest here:

Health Canada Approves XEOMIN (IncobotulinumtoxinA) for Treatment of Post-Stroke Lower Limb Spasticity

XEOMIN® (incobotulinumtoxinA) got approval from Health Canada for treating spasticity in adults in the post-stroke lower limb. A significant step in healthcare history for Canada, this is yet another vital milestone in the wider application for XEOMIN, through which healthcare providers can eventually treat upper and lower limb spasticity in the same patient by combining the two limbs into a total of 600 units. With this label expansion for XEOMIN, its basal role is now underpinned as a fundamental tool in neurological rehabilitation improvement(NOT GOOD ENOUGH! Survivors want 100% recovery!  GET THERE!) of ambulation to a reduction in pain. Every year, more than 109,000 strokes adversely affect Canadians. Of this number, a greater percentage of survivors become spastic one year after their stroke. This would be the sixth therapeutic use added to XEOMIN in Canada after others such as cervical dystonia, upper limb spasticity, and chronic sialorrhea.